Search

View selected items
Save to my bookmarks
Export citations
Download PDF (zip)
Save to Kindle
Save to Dropbox
Save to Google Drive
Save content to
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to .

To save content items to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Please be advised that item(s) you selected are not available.
You are about to save
Your Kindle email address

Please provide your Kindle email.

@free.kindle.com @kindle.com (service fees apply)

By using this service, you agree that you will only keep content for personal use, and will not openly distribute them via Dropbox, Google Drive or other file sharing services

1 results

25 - Future research: a clinical prospective
from Part V - Conclusions and future perspectives
- By Carlos A. Fontes Ribeiro, Department of Pharmacology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Edited by Jerzy Majkowski, Blaise F. D. Bourgeois, Harvard University, Massachusetts, Philip N. Patsalos, Institute of Neurology, London, Richard H. Mattson, Yale University, Connecticut
Book:

Antiepileptic Drugs

Published online:

07 September 2009

Print publication:

26 May 2005, pp 458-474
- Chapter
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation
Summary

Monotherapy implies the use of a single active entity and its advantages are recognized. The inappropriate application of drug combinations has been frequently coupled with inadequate recognition or understanding of epileptic syndromes. Pharmacovigilance is obligatory and must be improved for the study of drug interactions. Many studies suggest that multiple neurotransmitters and subtypes of their receptors are involved in the abnormal neuronal excitability that underlies some models of the epilepsies. Studies designed to test efficacy of drug combinations can be observational or experimental. For many antiepileptic drugs (AEDs), therapeutic serum level ranges are more or less well defined. In rational polypharmacy (RP), it is necessary to correlate serum levels with clinical efficacy since the combined drugs may be more active if the serum levels attained by each one in combination therapy are similar to those attained when the drug is used in monotherapy.

Search Results

Refine search

Refine search

Actions for selected content:

1 results

25 - Future research: a clinical prospective

Summary

Search Results

Refine search

Refine search

Actions for selected content:

Save Search

1 results

25 - Future research: a clinical prospective

Summary